BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Kinex Pharmaceuticals Converting from a LLC to a C-Corporation


1/4/2013 9:51:25 AM

BUFFALO, N.Y., Jan. 4, 2013 /PRNewswire/ --Kinex Pharmaceuticals today announced that it has converted the company from a Limited Liability Corporation into a C-Corporation, a planned strategic step to help drive future growth.

"Converting to a C-Corporation structure provides additional opportunity to access capital markets and funding sources not typically afforded under LLC structure and is the next logical phase in the evolution of the Company. It positions Kinex to maximize value for our share and stakeholders," said Flint Besecker, Chairman of the Audit and Finance committee. Mr. Besecker has held a number of nationwide executive positions in the healthcare and financial industry, including Care Investment Trust, CIT Healthcare, GE Healthcare Financial Services, Heller Healthcare Finance and Healthcare Financial Partners.

Jean-Pierre Sommadossi, PhD, board member and co-founder of Pharmasset and founder and former Chairman and CEO of Idenix, added, "Kinex's pipeline continues to expand and advance clinically. This new structure will allow Kinex to explore various strategic options as we move our programs forward. This conversion also addresses the needs of shareholders as well as current and future partners."

About Kinex Pharmaceuticals, LLC

Kinex Pharmaceuticals, headquartered in Buffalo, New York, USA, is using its proprietary technologies Mimetica and Opal to discover and develop novel drugs for oncology and immune-modulatory diseases. More information of Kinex Pharmaceuticals can be found at www.kinexpharma.com

Kinex Inquiries:

Patrick Gallagher
Vice President, Business Development and Investor Relations
Kinex Pharmaceuticals
701 Ellicott Street
Buffalo, NY 14203
pgallagher@kinexpharma.com

SOURCE Kinex Pharmaceuticals


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->